Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Temperature-based MHC class-I multimer demonstrate applicability across major MHC-I gene families for monitoring CD8+ T cell responses. Easy high-throughput peptide exchange potential, enhancing ...

An exploratory study to predict the efficacy and prognosis of immunotherapy for extensive-stage small cell lung cancer based on peripheral blood dynamic immune profiles.

Multiomic evaluation of TEV-56278, a PD-1-targeted attenuated IL-2 molecule, in a human ex vivo tumor model and association with immune activation with enhanced effector CD8 T cell selectivity.

Expanded CAR T cells were predominantly CD4–CD8 double-negative and EBER negative. Replication-competent lentivirus was undetectable in the blood at 6 and 12 months after cilta-cel therapy.

Peripheral blood CD4+/CD8+ t cell ratio predicts HBsAg clearance in inactive HBsAg carriers treated with peginterferon alpha Peer-Reviewed Publication Xia & He Publishing Inc.

Abstract. CD4 T cells have long been known to be critical for priming CD8 T cells, a process referred to as CD4 T cell help. Recent data have suggested that CD4 help may be delivered at the surface of ...

MHC-II microglia are in proximity to infiltrating CD8+ T cells both in the 5xFAD and human brain. Pharmacological inhibition of the IFN-response pathway in 5xFAD mice reduced myelin damage and ...

Secreted cytokines and cell surface markers (CD4, CD8) were stained with fluorescent detection antibodies, followed by analysis and sorting with a cell sorter. (D) The distribution of secretion ...